LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.

    Bergeron, Anthony / Bertaut, Aurélie / Beltjens, Françoise / Charon-Barra, Céline / Amet, Alix / Jankowski, Clémentine / Desmoulins, Isabelle / Ladoire, Sylvain / Arnould, Laurent

    British journal of cancer

    2023  Volume 129, Issue 1, Page(s) 122–134

    Abstract: Background: HER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We aimed to estimate them between primary and recurrent tumours, and identify predictive factors.: ... ...

    Abstract Background: HER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We aimed to estimate them between primary and recurrent tumours, and identify predictive factors.
    Methods: We compared the HER2 status, and clinical and pathological characteristics by its evolution category (stable or changed), between all primary BCs and matched recurrences registered in our database in 2000-2020 (n = 512).
    Results: HER2-low tumours were the most prevalent at diagnosis (44.9%), followed by HER2-negative tumours (39.3%). HER2 status significantly changed in 37.3% of recurrences, mainly of HER2-negative and HER2-low tumours. HER2-negative tumours which relapsed as HER2-low significantly more frequently expressed oestrogen receptors (ER) and recurred later than stably HER2-negative tumours. Changed HER2 status in distant metastases correlated with lower proliferation rates and higher ER expression in primary tumours, and among metastases of hormone receptor-positive (HR+) tumours-with weak progesterone receptor (PR) expression in primary tumours.
    Conclusions: HER2 status changes with BC progression, with enrichment of HER2-low tumours in advanced stages. The ER+/PR- status, low proliferation index and time to late recurrence correlated with these changes. These findings highlight the need of retesting recurrences, especially of HR + primary tumours, to identify candidates for new anti-HER2 therapies.
    MeSH term(s) Humans ; Female ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Breast Neoplasms/genetics ; Breast Neoplasms/therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Disease Progression ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism
    Chemical Substances Receptor, ErbB-2 (EC 2.7.10.1) ; Receptors, Estrogen ; Receptors, Progesterone ; Biomarkers, Tumor
    Language English
    Publishing date 2023-04-29
    Publishing country England
    Document type Journal Article
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/s41416-023-02287-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.142: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Impact of complete surgical staging on survival of patients with early-stage (FIGO I or II) ovarian cancer: Data from the Cote d'Or Registry of Gynecological Cancers from 1998 to 2015.

    Michel, Eloïse / Mamguem Kamga, Ariane / Amet, Alix / Padeano, Marie-Martine / Fumet, Jean-David / Favier, Laure / Bengrine Lefevre, Leila / Beltjens, Françoise / Arnould, Laurent / Dabakuyo, Sandrine / Costaz, Hélène

    Bulletin du cancer

    2023  Volume 110, Issue 4, Page(s) 352–359

    Abstract: Introduction: Early-stage ovarian cancer represents 20 to 33% of all ovarian cancers and is thus quite rare in France, with around 1200 new cases per year. No study to date has convincingly demonstrated the utility of lymphadenectomy in early-stage ... ...

    Abstract Introduction: Early-stage ovarian cancer represents 20 to 33% of all ovarian cancers and is thus quite rare in France, with around 1200 new cases per year. No study to date has convincingly demonstrated the utility of lymphadenectomy in early-stage ovarian cancer. We sought to evaluate the impact on overall survival of complete surgical staging in patients management for FIGO stage I and II ovarian cancer.
    Methods: We performed a retrospective observational study using data from the Cote d'Or Registry of Gynecological Cancers. We included patients with invasive early stage epithelial ovarian cancer (FIGO stages I and II), diagnosed between 1 January 1998 and 31 December 2015.
    Results: A total of 179 patients were included in the study. Patients who had lymphadenectomy were younger on average (P<0.001) and had fewer comorbidities (P=0.03). Lymphadenectomy was performed during the first surgery in 59.2% of cases (58 patients) and during a second, re-staging surgery in 40.8% (n=40). When complete surgical staging was performed, the rate of up-staging (to at least FIGO stage III) was 11.2% (11/98). The median follow-up was 8.4 years. At the study, 31.6% patients with complete surgical staging had died and 48.4% patients also died in the group without lymphadenectomy, HR 0.59 CI [0.36-0.97] P<0.04.
    Conclusion: In patients with early-stage ovarian cancer, complete surgical staging appears to yield a benefit in terms of overall survival. In 10 to 15% of cases, it leads to upstaging, with the resultant indication for maintenance therapy, which has also shown a survival benefit.
    MeSH term(s) Humans ; Female ; Neoplasm Staging ; Ovarian Neoplasms/pathology ; Carcinoma, Ovarian Epithelial/surgery ; Lymph Node Excision ; Retrospective Studies ; Registries
    Language English
    Publishing date 2023-02-17
    Publishing country France
    Document type Observational Study ; Journal Article
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2023.01.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.15: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Impact of therapeutic strategy on disease-free and overall survival of early-stage cervical cancer: Surgery alone versus preoperative radiation.

    Mahiou, Katia / Vincent, Laura / Peignaux-Casasnovas, Karine / Costaz, Hélène / Padeano, Marie-Martine / Amet, Alix / Dabakuyo, Sandrine / Mamguem Kamga, Ariane / Bengrine-Lefevre, Leila / Coutant, Charles

    Cancer reports (Hoboken, N.J.)

    2023  Volume 6, Issue 5, Page(s) e1823

    Abstract: Background and objectives: There is no international consensus for management of early-stage cervical cancer (ESCC). This study aimed to retrospectively investigate disease-free survival (DFS) and overall survival (OS) in patients with ESCC according to ...

    Abstract Background and objectives: There is no international consensus for management of early-stage cervical cancer (ESCC). This study aimed to retrospectively investigate disease-free survival (DFS) and overall survival (OS) in patients with ESCC according to the therapeutic strategy used, surgery alone versus preoperative radiation following by surgery.
    Methods: Data were retrospectively collected from 1998 to 2015 using the Gynecological Cancer Registry of the Côte d'Or. The inclusion criteria were FIGO 2018 ≤ IB2; squamous cell carcinoma, adenocarcinoma or adenosquamous type. Survival curves were compared using the log-rank test.
    Results: One hundred twenty-six patients were included. Median survival was 90 months. There was no significant difference in DFS (HR = 0.91, 95%CI [0.32-2.53], p = 0.858) or in OS between surgery alone versus preoperative radiation following by surgery (HR = 0.97, 95%CI [0.31-2.99], p = 0.961). In the subgroup of patients with stage ≥IB1, there was no significant difference in DFS (HR = 3.26, p = 0.2) or in OS (HR = 3.87, p = 0.2).
    Conclusion: Our study did not identify any difference in survival according to the treatment strategy. Preoperative radiation following by surgery can be an alternative to surgery alone for ESCC.
    MeSH term(s) Female ; Humans ; Uterine Cervical Neoplasms/radiotherapy ; Uterine Cervical Neoplasms/surgery ; Retrospective Studies ; Neoplasm Staging ; Carcinoma, Squamous Cell/radiotherapy ; Carcinoma, Squamous Cell/surgery ; Disease-Free Survival
    Language English
    Publishing date 2023-04-19
    Publishing country United States
    Document type Journal Article
    ISSN 2573-8348
    ISSN (online) 2573-8348
    DOI 10.1002/cnr2.1823
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

    Roussot, Nicolas / Constantin, Guillaume / Desmoulins, Isabelle / Bergeron, Anthony / Arnould, Laurent / Beltjens, Françoise / Mayeur, Didier / Kaderbhai, Courèche / Hennequin, Audrey / Jankowski, Clémentine / Padeano, Marie Martine / Costaz, Hélène / Jacinto, Sarah / Michel, Eloise / Amet, Alix / Coutant, Charles / Costa, Brigitte / Jouannaud, Christelle / Deblock, Mathilde /
    Levy, Christelle / Ferrero, Jean-Marc / Kerbrat, Pierre / Brain, Etienne / Mouret-Reynier, Marie-Ange / Coudert, Bruno / Bertaut, Aurélie / Ladoire, Sylvain

    European journal of cancer (Oxford, England : 1990)

    2024  Volume 202, Page(s) 114037

    Abstract: Background: The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional ... ...

    Abstract Background: The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype.
    Patients and methods: Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score. We compared the prognostic stratification abilities of the CPS+EG in HER2-low and HER2-0 eBC, analyzing ER+ and ER- tumors separately.
    Results: In ER+ eBC, the CPS+EG scoring system seems to retain a prognostic value, both in HER2-low and HER2-0 tumors, by distinguishing populations with significantly different outcomes (good: score 0-1, poor: score 2-3, and very poor: score 4-5). Using C-indices for DFS and OS, CPS+EG provided the highest prognostic information in ER+ eBC, especially in HER2-0 tumors. In contrast, in ER- eBC, the CPS+EG does not appear to be able to distinguish different outcome groups, either in HER2-low or HER2-0 tumors. In ER- eBC, C-indices for DFS and OS were highest for pathological stage, reflecting the predominant prognostic importance of residual disease in this subtype.
    Conclusions: HER2-low status does not influence the prognostic performance of the CPS+EG score. Our results confirm the usefulness of the CPS+EG score in stratifying the prognosis of ER+ eBC after NAC, for both HER2-0 and HER2-low tumors. For ER- eBC, HER2-low status does not influence the performance of the CPS+EG score, which was lower than that of the pathological stage alone.
    MeSH term(s) Humans ; Female ; Prognosis ; Breast Neoplasms/pathology ; Neoadjuvant Therapy/methods ; Retrospective Studies ; Neoplasm Staging ; Receptor, ErbB-2 ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Disease-Free Survival
    Chemical Substances Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2024-03-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2024.114037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

    Ilie, Silvia Mihaela / Briot, Nathalie / Constantin, Guillaume / Roussot, Nicolas / Ilie, Alis / Bergeron, Anthony / Arnould, Laurent / Beltjens, Françoise / Desmoulin, Isabelle / Mayeur, Didier / Kaderbhai, Courèche / Hennequin, Audrey / Jankowski, Clémentine / Padeano, Marie Martine / Costaz, Helène / Amet, Alix / Coutant, Charles / Coudert, Bruno / Bertaut, Aurélie /
    Ladoire, Sylvain

    Breast cancer (Tokyo, Japan)

    2023  Volume 30, Issue 6, Page(s) 997–1007

    Abstract: Background: Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity to treatment and prognosis.: Patients and ... ...

    Abstract Background: Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity to treatment and prognosis.
    Patients and methods: To investigate chemosensitivity and long-term prognosis of HER2-low early breast cancer (eBC), compared to HER2-0 tumors, we retrospectively retrieved clinicopathological characteristics, response to treatment, and survival data from 511 patients treated for eBC with neoadjuvant chemotherapy (NAC) in a French cancer center between 2007 and 2018. Factors associated with the achievement of pathologic complete response (pCR) and survival were studied among hormone receptor positive (HR+) and negative (HR-) eBC.
    Results: A total of 280 HR+ (61% HER2-low), and 231 HR- (28% HER2-low) eBC were included. We found classical clinicopathological factors usually associated with chemosensitivity and prognosis, in both HR+ and HR- eBC. By uni- and multivariable analysis, HER2 status (low vs 0) was not independently associated with pCR, either in HR+ or HR- eBC. Relapse free (RFS) and overall survival (OS) were not significantly different between HER2-low and HER2-0 among HR+ tumors. In contrast, among HR- negative tumors, RFS and OS were slightly better in HER2-0 eBC by univariable but not by multivariable analysis.
    Conclusions: In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/pathology ; Neoadjuvant Therapy ; Retrospective Studies ; Receptor, ErbB-2/metabolism ; Neoplasm Recurrence, Local/drug therapy ; Prognosis ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant
    Chemical Substances Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2023-08-10
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-023-01490-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5536: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top